Chimeric antigen receptor

Chimeric Antigen Receptor

Seattle Children's Spins Out BrainChild Bio

Seattle Children's has recently spun out BrainChild Bio, a startup focused on developing innovative therapies for incurable brain cancers. The startup will be renting space in the Seattle Children's Building Cure, which opened its doors in downtown Seattle in 2019. This move underscores the commitment to advancing research and treatment options for patients facing challenging diagnoses.

Revolutionizing Cancer Treatment

BrainChild Bio's work in the field of chimeric antigen receptor (CAR) therapies holds promise for revolutionizing cancer treatment. By harnessing the power of the immune system to target and destroy cancer cells, CAR therapies offer new hope for patients with difficult-to-treat forms of cancer. The collaboration between Seattle Children's and BrainChild Bio highlights the importance of partnerships in driving forward progress in the fight against cancer.